InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,344.16
(
0.47%
)
US TECH 100
18,024.00
(
0.56%
)
Dow Jones
39,497.54
(
0.13%
)
Brent Oil
79.49
(
0.00%
)
Bitcoin
60,724.65
(
-0.25%
)
Post# of 252819
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120250
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: MotionMan post# 88876

Monday, 01/11/2010 9:11:34 PM

Monday, January 11, 2010 9:11:34 PM

Post# of 252819
MNTA:

listening to Teva's Jan 7th webcast. Bill Marth was adamant about believing that generic Copaxone applicants will have to run comprehensive clinical studies. He does not believe anyone can fully characterize a polypeptide with permutations up to 10 to the 28th power.

The 10^28 figure is irrelevant. MNTA replicates branded Copaxone by reverse engineering the process that generates the permutations, not by replicating each of the permutations directly. Please see #msg-30647865, which is an entry in the MNTA ReadMeFirst.

Bill Marth knows all this, of course.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up